MSB11022 in Moderate to Severe Chronic Plaque Psoriasis
Status:
Completed
Trial end date:
2017-12-18
Target enrollment:
Participant gender:
Summary
The purpose of this study was to compare the efficacy, safety and immunogenicity of MSB11022
and Humira® in adult subjects with moderate to severe chronic plaque type psoriasis.
Phase:
Phase 3
Details
Lead Sponsor:
EMD Serono Research & Development Institute, Inc. Fresenius Kabi SwissBioSim GmbH